For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...